Ebixa (Memantine) - Indication and Maximum Geriatric Dose
Ebixa (memantine hydrochloride) is indicated for moderate to severe Alzheimer's disease, with a maximum dose of 20 mg/day in elderly patients (or 28 mg/day for extended-release formulations where available).
Primary Indication
Ebixa is an NMDA receptor antagonist approved specifically for moderate to severe dementia of the Alzheimer's type 1, 2. The drug can be used either as monotherapy or in combination with cholinesterase inhibitors (donepezil, rivastigmine, galantamine) 1, 3.
Evidence Base for Efficacy
The evidence shows that memantine provides:
- Statistically significant improvements in cognition (measured by ADAS-cog and SIB scales) and global function (CIBIC-plus scale) 1
- Quality of life benefits with improvements in caregiver burden and resource utilization 1
- However, the guideline evidence notes these improvements are "statistically significant, but not clinically important" in some measures 4, 1
The strongest evidence supports use in moderate to severe Alzheimer's disease, with more equivocal data for mild to moderate disease 2.
Maximum Dose in Geriatric Patients
Standard Immediate-Release Formulation
- Maximum dose: 20 mg/day 5, 6, 7
- Administered as 10 mg twice daily 5
- Dose titration is critical: Increase by 5 mg/day per week over the first 4 weeks to reach the target dose of 20 mg/day 8
- Preferably taken in the morning 7
Extended-Release Formulation (where available)
- Maximum dose: 28 mg once daily 5, 9
- This formulation improves adherence through once-daily dosing but has not demonstrated superior clinical efficacy compared to the 20 mg twice-daily immediate-release formulation 9
Important Clinical Considerations
Safety Profile
Memantine is generally well tolerated in elderly patients with an adverse event profile similar to placebo 6. Common side effects include:
- Headache, dizziness, diarrhea 5
- Nausea and agitation 1
- Withdrawal rates due to adverse effects: 9-12% (similar to placebo at 7-13%) 1
Key Advantages in Geriatric Population
- Low drug interaction potential - can be safely combined with cholinesterase inhibitors and is suitable for elderly patients on multiple medications 7
- Minimal metabolism with complete oral absorption and long half-life (60-100 hours) 7
- Delays need for full-time care, which translates to cost savings 6
Pitfalls to Avoid
- Do not rush titration - slow dose escalation over 4 weeks minimizes side effects and improves tolerability 7, 8
- Not indicated for mild Alzheimer's disease - evidence is equivocal for mild to moderate disease; strongest evidence is for moderate to severe disease 2
- The 28 mg extended-release formulation does not provide clinically superior outcomes despite higher dosing 9
Additional Indications (Limited Evidence)
While the primary FDA-approved indication is Alzheimer's disease, memantine has also shown benefit in:
- Vascular dementia (moderate evidence) 4, 1
- Lewy body dementia (strong recommendation per recent guidelines) 3
- Parkinson's disease dementia (conditional recommendation) 3
The 2025 Korean Dementia Association guidelines provide the most recent evidence-based recommendations, strongly supporting memantine for moderate to severe AD with demonstrated cognitive and functional improvements 3.